MAPKAPK2 and ovarian serous tumor: Nanoplex‐mediated silencing of MK2 profoundly sensitized high‐grade serous ovarian tumors to concurrent platinum/taxane chemotherapy in vivo, improved overall survival by 37%, and decreased metastatic spread to the lungs without observable toxic side effects.